Searchable abstracts of presentations at key conferences in endocrinology

ea0063gp53 | Acromegaly and GH | ECE2019

Efficacy and safety of once-weekly somapacitan in adult growth hormone deficiency (AGHD) confirmed in a 53-week REAL-1 trial extension

Johannsson Gudmundur , Gordon Murray , Rasmussen Michael Hojby , Hakonsson Ida Holme , Svaerke Claus , Tahara Shigeyuki , Takano Koji , Biller Beverly MK

Background: Following the 34-week, double-blind, placebo-controlled main phase of REAL-1 (NCT02229851), this open-label trial extension evaluated efficacy and safety of somapacitan in patients aged 23–79 years with AGHD, for an additional 52 weeks (8 weeks’ dose titration followed by 44 weeks’ fixed dose treatment; 86 weeks’ treatment in total).Methods: Patients completing the main trial entered the extension: 1) somapacitan-treated p...

ea0063gp157 | Cushing's | ECE2019

DNA Methylation and fMRI responses in patients with Cushing’s syndrome in remission – suggestions of a functional link between hypercortisolism and neurocognitive dysfunction

Glad Camilla , Andersson-Assarsson Johanna , Stomby Andreas , Dahlqvist Per , Nyberg Lars , Bergthorsdottir Ragnhildur , Johannsson Gudmundur , Ragnarsson Oskar

Introduction: Compared with healthy controls, women with Cushing’s syndrome (CS) in long-term remission have reduced functional brain responses during episodic and working memory testing and decreased overall levels of DNA methylation in blood cells. Here, we sought to test the hypothesis that functional brain responses in the prefrontal cortex and hippocampus are related to epigenetic changes in subjects with CS in long-term remission.Methods: In t...

ea0041oc13.3 | Pituitary Clinical | ECE2016

Increased glucocorticoid replacement doses are associated with excess mortality in patients with non-functioning pituitary adenoma

Hammarstrand Casper , Hallen Tobias , Andersson Eva , Skoglund Thomas , Nilsson Anna G , Ragnarsson Oskar , Johannsson Gudmundur , Olsson Daniel S

Background: Patients with secondary adrenal insufficiency have an excess mortality. Data concerning the influence of the glucocorticoid replacement regime on mortality is sparse.Objective: To investigate if the total daily dose of glucocorticoid replacement has an effect on mortality in patients with non-functioning pituitary adenoma (NFPA).Method: Patients with NFPA treated for hypopituitarism in the western region of Sweden were ...

ea0014p245 | (1) | ECE2007

Growth hormone Reduces Inflammation in Postmenopausal Women with Abdominal Obesity: a 12-month randomized placebo-controlled trial

Franco Celina , Andersson Björn , Lönn Lars , Bengtsson Bengt-Æke , Svensson Johan , Johannsson Gudmundur

Context: Abdominally obese individuals have relative hyposomatotropism, elevated serum markers of inflammation, and increased risk of cardiovascular disease (CVD).Objective: The aim was to study the effect of GH treatment on serum levels of inflammatory markers and vascular adhesion molecules in postmenopausal women with abdominal obesity.Design: Forty postmenopausal women aged 51–63 yrs with abdominal obesity received GH (0.6...

ea0056p759 | Neuroendocrinology | ECE2018

Body composition and bone health in patients treated for craniopharyngioma: a retrospective 10 year follow-up study

van Santen Selvetta S. , Hammarstrand Casper , Olsson Daniel , Wijnen Mark , Johannsson Gudmundur , van der Lely Aart J. , Neggers Sebastian

Introduction: Craniopharyngiomas are benign tumors in the suprasellar region that have encouraging survival rates between 77-93%. Unfortunately, long-term sequelae are frequent, resulting in excessive endocrine and metabolic morbidity, including premature cardiovascular disease and reduced bone health.Objective: To determine the prevalence of unfavorable body composition and low bone mineral density (BMD) in patients with craniopharyngioma.<p class="...

ea0099p420 | Adrenal and Cardiovascular Endocrinology | ECE2024

Different metabolic pathways associated with total cortisol exposure and the cortisol time profile: A randomized cross-over clinical trial

McQueen Johanna , Garner Terence , Chantzichristos Dimitrios , Lennernas Hans , Espiard Stephanie , Ragnarsson Oskar , Bergthorsdottir Ragnhildur , Skrtic Stanko , Stevens Adam , Johannsson Gudmundur

Context: Excess cortisol exposure and disruption of the circadian cortisol profile are both associated with adverse clinical outcome.Objective: The aim of this study was to identify unique metabolites and metabolic pathways associated with total cortisol exposure and the cortisol time profile.Design: A randomized, 12-week, two period, cross-over clinical trial.Patients and interventions: Eighteen adults with ...

ea0081p415 | Pituitary and Neuroendocrinology | ECE2022

Effects of somapacitan on glucose metabolism in adults with GH deficiency

Johannsson Gudmundur , MK Biller Beverly , Fukuoka Hidenori , Ho Ken , Hojby Rasmussen Michael , Nedjatian Navid , Svaerke Claus , CJ Yuen Kevin , Takahashi Yutaka

Somapacitan is a once-weekly, long-acting growth hormone (GH) derivative approved for the treatment of adult GH deficiency (AGHD). Our objective was to evaluate the effects of somapacitan on glucose metabolism compared with daily GH or placebo in patients with AGHD using data from three previously published phase 3 trials: REAL 1 (NCT02229851), REAL 2 (NCT02382939) and REAL Japan (NCT03075644). REAL 1 was a randomised, placebo-controlled (double-blind) and active-controlled (o...

ea0067o33 | Oral Presentations | EYES2019

Bone health and final height in craniopharyngioma patients

van Santen Selveta S , Olsson Daniel S , Hammarstrand Casper , Wijnen Mark , Johannsson Gudmundur , van der Lely Aart J , Heuvel-Eibrink MM van den , JCMM Neggers Sebastian

Objective: Craniopharyngioma (CP) is a benign tumor of the sellar/hypothalamic region. It is associated with endocrinopathies, which may potentially impair bone health. Our objective was to determine bone health status in CP patients.Methods: In this retrospective study, Dutch/Swedish CP patients were included if data was available on fractures, bone mineral density (BMD) (T/Z-score), or final height (age >18 years). Data is presented as mean±<s...

ea0063gp117 | Calcium and Bone 2 | ECE2019

Bone health and final height in craniopharyngioma patients.

Santen Selveta S. van , Hammarstrand Casper , Olsson Daniel S. , Wijnen Mark , Johannsson Gudmundur , Lelij Aart J van der , Heuvel-Eibrink Marry M. van den , Neggers Sebastian JCMM

Introduction: Craniopharyngioma (CP) is a benign tumor of the sellar/hypothalamic region. It is associated with excess mortality, obesity and endocrinopathies. These endocrinopathies may influence bone health, and increase the risk of fractures.Methods: In this retrospective study, Dutch/Swedish patients with CP were included if data was available on final height (at age >18 years) or DXA-scan results. Information from the first and last DXA-scans we...

ea0063p437 | Adrenal and Neuroendocrine Tumours 2 | ECE2019

Hypoadrenalism in Advanced HIV

Ross Ian , Millar Robert , Mofokeng Thabiso , Grossman Ashley , Dave Joel , Levitt Naomi , Pillay Tahir , Erasmus Rajiv , Raubenheimer Peter , Dandara Collet , Johannsson Gudmundur

Background: Large populations of HIV and tuberculosis occur in South Africa and, amongst these patients, Addison’s disease is probably underdiagnosed. Preliminary data in 60 HIV-positive patients with a CD4 count less than 100 cells/mm3 showed that the overall prevalence of hypoadrenalism was 6.7%, with 1 patient having primary hypoadrenalism and 3 patients having central hypoadrenalism. This report describes the prevalence of hypoadrenalism and its association...